Trials are continued after interim analysis if there is a reasonable expectation that they will be successful.

Continuation to completion is positive news.

Trial stoppage with approval at interim is obviously better, but uncommon.

We of course are also all speculating based on the the press release.

I don't see anything negative, any more than continuation as safety evaluation at 100 patients was negative. Leronlimab marches on.